Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:32:45 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:ARWR from 2023-05-04 to 2024-05-03 - 37 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
2024-04-29 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
2024-04-26 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
2024-04-24 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
2024-04-24 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
2024-04-16 09:00U:ARWRNews ReleaseTurnstone Biologics Appoints William Waddill to its Board of Directors
2024-04-07 09:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
2024-04-01 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2024-03-25 08:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
2024-03-08 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
2024-03-04 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
2024-02-06 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
2024-01-22 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
2024-01-05 17:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Closes Underwritten Offering with Gross Proceeds of $450.0 Million
2024-01-03 07:00U:ARWRNews ReleaseArrowhead Pharmaceuticals Announces Pricing of $450.0 Million Underwritten Offering of Common Stock
2023-12-29 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-12-21 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
2023-12-20 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-11-29 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
2023-11-28 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
2023-11-21 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
2023-11-16 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
2023-11-13 09:30U:ARWRNews ReleaseArrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
2023-11-02 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Present New Phase 2 Clinical Data on Cardiometabolic Pipeline at AHA 2023
2023-10-03 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
2023-09-27 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-09-11 07:30U:ARWRNews ReleaseArrowhead Presents Data on Pulmonary Pipeline at ERS 2023
2023-09-01 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
2023-08-07 16:01U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
2023-07-17 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1/2 Study of ARO-DUX4 for Facioscapulohumeral Muscular Dystrophy
2023-07-06 16:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2023-06-27 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate a Phase 1 Study of ARO-SOD1
2023-06-24 08:15U:ARWRNews ReleaseArrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease
2023-06-01 07:30U:ARWRNews ReleaseArrowhead Hosts R&D Day Highlighting Its Pipeline of RNAi Therapeutics
2023-05-23 07:30U:ARWRNews ReleaseArrowhead Presents Interim Data from ARO-ANG3 Phase 2 GATEWAY Study in Patients with HoFH
2023-05-16 07:30U:ARWRNews ReleaseArrowhead Pharmaceuticals Completes Enrollment of Phase 3 PALISADE Clinical Trial Evaluating ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome
2023-05-15 16:00U:ARWRNews ReleaseArrowhead Pharmaceuticals to Participate in Upcoming Conferences